New MOAs in prostate cancer treatment - what’s next?

Abemaciclib potential therapeutic option for Kaposi sarcoma

ASCO 2025: Latest in EGFR positive NSCLC

Nivolumab/ipilimumab followed by BRAF/MEK inhibitors preferred sequence for BRAF-positive advanced melanoma

Sasanlimab BCG combo improves outcomes in high-risk NMIBC

Neoadjuvant PD-1 blockade enables organ preservation in early dMMR tumours without surgery

Vepdegestrant could extend PFS for some ESR1-mutated advanced breast cancers

Olaparib boosts chemotherapy’s impact on BRCA-mutated breast cancer

WRN inhibitor shows promise in patients with MSI and/or dMMR advanced solid tumours

Olaparib plus pembrolizumab shows promising results in BRCA mutated cancers

Metastasis-directed radiotherapy shows good prognosis for oligometastatic kidney cancer

Circulating tumour DNA can guide adjuvant immunotherapy for mismatch repair-deficient tumours